{
    "title": "AstraZeneca's Lynparza shows further promise in prostate cancer study",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8252639/AstraZenecas-Lynparza-shows-promise-prostate-cancer-study.html",
    "date": "2020-04-24",
    "keywords": [
        "cancer",
        "astrazeneca",
        "prostate",
        "study",
        "drug",
        "goal",
        "survival",
        "castrationresistant",
        "merck",
        "latestage",
        "effectiveness",
        "company",
        "lynparza",
        "brca12",
        "gene",
        "anticancer",
        "enzalutamide",
        "httpswwwastrazenecacommediacentrepressreleases2020lynparzashowsoverallsurvivalinprostatecancerhtml",
        "potential",
        "use",
        "brca",
        "atm",
        "dna",
        "executive",
        "vp",
        "oncology",
        "rampd",
        "treatment",
        "class",
        "parp",
        "chemotherapy",
        "asset",
        "breast",
        "society",
        "reporting",
        "pushkala",
        "aripaka",
        "bengaluru",
        "editing",
        "graham",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}